BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
SUBSCRIBE
BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
BullScope
No Result
View All Result
Home Market News

JPMorgan Chase’s third-quarter profit falls 28 percent as revenue slumps and credit costs rise

Moe Alsumidaie by Moe Alsumidaie
October 14, 2026
in Market News
0
74
SHARES
1.2k
VIEWS
Share on XShare on LinkedInShare on Facebook

JPMorgan Chase reported net income of $15,305 million in the third quarter of 2026, down 28 percent from $21,155 million in the second quarter. Total net revenue on a managed basis declined 12 percent to $50,907 million, marking a sharp reversal from the first half’s momentum. The decline signals a contraction in both trading activity and lending spreads after a strong first half that had lifted nine-month net income 20 percent above the prior year’s comparable period.

Revenue fell to $50,907 million from $58,022 million in the second quarter, a drop the company did not offset with expense discipline; total noninterest expense held flat at $27,295 million. Pre-provision profit, the earnings available after operating costs but before credit losses, fell 23 percent to $23,612 million. The provision for credit losses rose 9 percent to $2,743 million from $2,515 million in the prior quarter, though it remained below the $3,403 million provision in the third quarter of 2025. For the nine months ended September 30, 2026, net income reached $52,954 million, up 20 percent from $44,023 million in the same period of 2025, and total net revenue on a managed basis climbed 15 percent to $159,465 million.

What it means

The third-quarter decline appears driven by a seasonal pullback in capital markets activity rather than fundamental deterioration in the bank’s underlying business. The nine-month results show the firm remains on track with revenue growth of 15 percent against the prior year, well ahead of the 2.8 percent growth JPMorgan reported for full-year 2025. The company did not provide revised guidance for the full year, leaving open whether management views the third-quarter weakness as temporary or the start of a broader slowdown.

Credit quality showed modest stress. The provision for credit losses in the third quarter of 2026 was 19 percent lower than in the third quarter of 2025, suggesting the bank’s loan portfolio has not deteriorated materially. The nine-month provision of $7,765 million was 19 percent below the prior year’s $9,557 million, indicating fewer charge-offs and lower expected losses than a year ago. However, the sequential rise in provisions from the second quarter hints that credit normalization may be underway as pandemic-era credit strength fades.

BullScope TerminalJPMORGAN CHASE & CO was the article. The engine is the product.Same yardsticks, any ticker: filed financials in, math-vs-mood out. Nothing here is advice; it is the evidence, organized.Run another company →

Capital ratios compressed modestly. The Common Equity Tier 1 ratio fell to 13.9 percent from 14.8 percent a year earlier, though the firm remains well above regulatory minimums. The decline reflects both the lower earnings in the quarter and the forward purchase commitment to acquire the Apple credit card portfolio, which the company entered in December 2025 with an expected closing approximately 24 months thereafter. This transaction will add consumer credit exposure and consume capital once it closes.

Return on tangible common equity fell to 20 percent in the third quarter from 29 percent in the second quarter, a compression that mirrors the earnings decline and suggests the quarter’s weakness was broad-based across business lines rather than concentrated in one segment.

What to watch

The fourth-quarter earnings release and full-year 2026 results, expected in January 2027, will clarify whether the third-quarter revenue decline represents a seasonal trough or the beginning of sustained pressure on capital markets revenue and lending margins. The timing of the Apple Card portfolio closing, now expected in late 2027 or early 2028, will also become clearer as the company approaches the 24-month window from the December 2025 commitment date.

Source: the company’s 8-K filed 2026-10-13 with the SEC.

BullScope publishes impersonal research for a general audience. Nothing here is personalized investment advice, and nothing here is a recommendation to buy or sell any security. As of publication, neither BullScope nor its operator holds a position in any security, covered or otherwise; we do not trade at all, and we accept no compensation from any company we cover. When a conflict of interest exists, we do not publish: companies that compensate our operator in any capacity, or about which our operator could hold nonpublic information, are barred from coverage automatically, as described in the conflicts policy in our methodology. Figures come from company filings and public data through our published methodology; forecasts are conditional scenarios, not predictions and not promises. Markets carry risk, including loss of principal. Consider your own situation, or consult a licensed adviser, before acting on anything you read.
BullScope TerminalYou just read JPMORGAN CHASE & CO’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →
Moe Alsumidaie

Moe Alsumidaie

Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.

Recommended For You

Abbott to split Nutrition into independent company with $8.5 billion in sales by end of 2027

by Moe Alsumidaie
October 22, 2026
0

Abbott announced plans to separate its Nutrition business into a standalone publicly traded company by the end of 2027, creating a $8.5 bil

Read moreDetails

GE Aerospace raises 2026 guidance as commercial services orders surge 58 percent

by Moe Alsumidaie
October 21, 2026
0

GE Aerospace lifted full-year profit and cash flow targets after third-quarter orders jumped 58 percent, driven by a backlog of over $170 b

Read moreDetails

Biohaven licenses Japan and Asia rights to Graves’ disease candidate for $80 million upfront and 20% royalties

by Moe Alsumidaie
October 19, 2026
0

Biohaven has licensed its lead extracellular IgG degrader, BHV-1300, to Ono Pharmaceutical for exclusive development and commercialization

Read moreDetails

UnitedHealth’s operating margin surges as medical cost discipline offsets revenue decline

by Moe Alsumidaie
October 15, 2026
0

UnitedHealth Group raised full-year earnings guidance to at least $20.50 per share after third-quarter operating earnings jumped 53 percent

Read moreDetails

Delta’s September quarter revenue surges 16 percent on yield growth as fuel costs eat into margins

by Moe Alsumidaie
October 12, 2026
0

Delta Air Lines posted September quarter revenue of $17.6 billion, up 16 percent from the prior year, but the airline's adjusted operating

Read moreDetails
Next Post

UnitedHealth's operating margin surges as medical cost discipline offsets revenue decline

Please login to join discussion
BullScope
The Research Terminal
Run any stock through the BullScope evidence engine. Filings in, evidence out. Every number explains itself.
Open the Terminal
A BullScope product

Related News

JPMorgan: Record Earnings, a 99th-Percentile Price Tag, and One Open Question

August 25, 2026

Viatris: The Stock Has Run 72% in a Year. The Filed Numbers Tell a More Complicated Story.

October 9, 2026

Indivior: Earnings Have Turned Positive. The Multiple Has Not Yet Moved in Step.

September 10, 2026
BullScope

BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.

Prefer BullScope.ai on Google

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

No Result
View All Result
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

Not enough quota to unlock this post
Unlock left : 0
Are you sure want to cancel subscription?
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.